Positive Two-Year Data for Telbivudine for the Treatment of Chronic Hepatitis B Presented at 2005 Digestive Disease Week (DDW) M
17 May 2005 - 7:05AM
PR Newswire (US)
Positive Two-Year Data for Telbivudine for the Treatment of Chronic
Hepatitis B Presented at 2005 Digestive Disease Week (DDW) Meeting
Telbivudine treatment nearly doubles proportion of patients
achieving clinical efficacy measures compared to lamivudine
CHICAGO, May 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals,
Inc. (NASDAQ:IDIX) today announced the presentation of interim
two-year results from an extended-treatment phase IIb clinical
trial for telbivudine demonstrating continuing advantages compared
to lamivudine across key efficacy endpoints through two years of
treatment in HBeAg-positive chronic hepatitis B patients. Further
analyses of the two-year data indicate that the link between early
and profound viral suppression and markers of improved clinical
outcomes that were demonstrated at one year extends through two
years of treatment. These data were presented today at the 2005
Digestive Disease Week meeting in Chicago, Illinois by Ching-Lung
Lai, M.D., lead investigator and Professor of Medicine and
Hepatology, Department of Medicine, University of Hong Kong. The
ongoing phase IIb clinical trial compares telbivudine monotherapy
and a combination of telbivudine and lamivudine, with lamivudine
monotherapy in 104 treatment-naive patients with HBeAg-positive
chronic hepatitis B. Patients receiving telbivudine monotherapy
achieved a 1.5 log10, or 30-fold, greater mean viral load reduction
compared to patients receiving lamivudine monotherapy at two years.
At two years, the percent of patients receiving telbivudine
monotherapy in whom levels of serum HBV DNA became undetectable by
a sensitive PCR-based assay was 71 percent, more than double that
of the 32 percent of patients receiving lamivudine monotherapy (p
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
More Idenix Pharmaceuticals (MM) News Articles